Loading...
Market
What will be the primary benefit observed in human trials of Anti-IL-11 drug by end of 2025?
2
Resolution / Starting Odds
Lifespan Extension • 25%
Cancer Reduction • 25%
Gray Hair Reduction • 25%
Other • 25%
Results published in peer-reviewed medical journals or clinical trial outcomes
Story
Study Shows Anti-IL-11 Drug Extends Lifespan of Mice by 25%, Reduces Cancer and Gray Hair
Jul 17, 2024, 04:25 PM
A recent study published in Nature has shown that inhibiting interleukin-11 (IL-11), a pro-inflammatory cytokine, can significantly extend the lifespan of mice. The research demonstrated that both genetic deletion and pharmacological inhibition of IL-11 increased the lifespan of laboratory mice by nearly 25%. The treated mice, referred to as 'supermodel grannies' due to their youthful appearance, were healthier, stronger, and exhibited fewer age-related health problems. The study found that male mice experienced a 22.5% increase in median lifespan. Additionally, the treatment reduced the incidence of cancer and gray hair. Anti-IL-11 therapies are already in human clinical trials, raising hopes for their potential application in extending human lifespan and improving healthspan.
View original story
Similar markets
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Lung fibrosis • 25%
Age-related diseases • 25%
Cancer • 25%
Other • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
More than 30% • 25%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by another regulatory body • 25%
Not approved by any major regulatory body • 25%
0%-10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%